Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lobular Breast Carcinoma in Situ: early-phase trial registry
A small indexed set (6 trials) with no open enrollment listed right now.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count
Lobular Breast Carcinoma in Situ: 6 US clinical trials tracked, none currently recruiting.
Lobular Breast Carcinoma in Situ is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition lobular-breast-carcinoma-in-situ
OPEN 0 | RECR 0% | LATE 1 | EARLY 2 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Lobular Breast Carcinoma in Situ has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lobular Breast Carcinoma in Situ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lobular Breast Carcinoma in Situ is recruiting below its size-band peers.
0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lobular Breast Carcinoma in Situ research.
Alliance for Clinical Trials in Oncology accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Lobular Breast Carcinoma in Situ enrolment sits around 112 participants.
Median target enrolment is 112 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Lobular Breast Carcinoma in Situ research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
SWOG Cancer Research Network
NCT04496739
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Virginia Commonwealth University
NCT02515110
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Alliance for Clinical Trials in Oncology
NCT01905046
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
National Cancer Institute (NCI)
NCT01077453
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT01869764
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
University of Chicago
NCT01706432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lobular Breast Carcinoma in Situ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lobular Breast Carcinoma in Situ trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lobular Breast Carcinoma in Situ page
6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Lobular Breast Carcinoma in Situ trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Alliance for Clinical Trials in Oncology sponsors the most Lobular Breast Carcinoma in Situ trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lobular Breast Carcinoma in Situ condition card totals 6 registered trials; most-linked intervention laboratory biomarker analysis; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.